Merck Halts Second PAH Drug Study Early on Strong Efficacy Results

Published on 31 Jan 2025 on Zacks · via Yahoo Finance

MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after...

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of Top 10 Best Dividend Stocks on Robinhood. In this article, we are...

Insider Monkey · via Yahoo Finance 1 Feb 2025

The most recent trading session ended with Merck (MRK) standing at $98.82, reflecting a -0.13% sh...

Zacks · via Yahoo Finance 31 Jan 2025

MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes af...

Zacks · via Yahoo Finance 31 Jan 2025

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is w...

Zacks · via Yahoo Finance 30 Jan 2025

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earning...

Zacks · via Yahoo Finance 30 Jan 2025

With its stock down 7.0% over the past three months, it is easy to disregard Merck (NYSE:MRK)....

Simply Wall St. · via Yahoo Finance 29 Jan 2025

Merck (NSE:PROR) & Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads...

Investing.com 29 Jan 2025

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, w...

Insider Monkey · via Yahoo Finance 29 Jan 2025

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market ope...

Zacks · via Yahoo Finance 28 Jan 2025

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earning...

Zacks · via Yahoo Finance 28 Jan 2025